Is Immuron Ltd (IMRN) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.9% / 30% | 36.7% / 30% | 25.0% / 30% | 1.86% / 5% | ✗ NOT HALAL |
| DJIM | 0.9% / 33% | 36.7% / 33% | 25.0% / 33% | 1.86% / 5% | ✗ NOT HALAL |
| MSCI | 0.7% / 33% | 27.9% / 33% | 19.0% / 33% | 1.86% / 5% | ✓ HALAL |
| S&P | 0.9% / 33% | 36.7% / 33% | 25.0% / 33% | 1.86% / 5% | ✗ NOT HALAL |
| FTSE | 0.7% / 33% | 27.9% / 33% | 19.0% / 50% | 1.86% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 63.7% | |
| Operating Margin | -47.2% | |
| Net Margin | -62.1% | |
| Return on Equity (ROE) | -39.7% | |
| Return on Assets (ROA) | -21.9% |
Cash Flow & Balance Sheet
| Free Cash Flow | -$6M |
| Total Debt | $71,855 |
| Debt-to-Equity | 1.6 |
| Current Ratio | 8.0 |
| Total Assets | $10M |
Price & Trading
| Last Close | $0.76 |
| 50-Day MA | $0.82 |
| 200-Day MA | $1.46 |
| Avg Volume | 45K |
| Beta | 0.4 |
|
52-Week Range
$0.68
| |
About Immuron Ltd (IMRN)
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Immuron Ltd (IMRN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Immuron Ltd is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Immuron Ltd's debt ratio?
Immuron Ltd's debt ratio is 0.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.7%.
What are Immuron Ltd's key financial metrics?
Immuron Ltd has a market capitalization of $8M, and revenue of $7M. The company maintains a gross margin of 63.7% and a net margin of -62.1%. Return on equity stands at -39.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.